Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.

导出 OA

翻译打印收藏纠错

第一作者： Kohei,Shitara

第一单位： National Cancer Center Hospital East, Kashiwa, Japan. kshitara@east.ncc.go.jp.;Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan. kshitara@east.ncc.go.jp.

作者： Kohei,Shitara ^[1] ; Yung-Jue,Bang ^[2] ; Satoru,Iwasa ^[3] ; Naotoshi,Sugimoto ^[4] ; Min-Hee,Ryu ^[5] ; Daisuke,Sakai ^[4] ; Hyun Cheol,Chung ^[6] ; Hisato,Kawakami ^[7] ; Hiroshi,Yabusaki ^[8] ; Yasuhiro,Sakamoto ^[9] ; Tomohiro,Nishina ^[10] ; Koichiro,Inaki ^[11] ; Yusuke,Kuwahara ^[12] ; Naoya,Wada ^[13] ; Fumitaka,Suto ^[12] ; Takeo,Arita ^[11] ; Masahiro,Sugihara ^[11] ; Zenta,Tsuchihashi ^[12] ; Kaku,Saito ^[12] ; Akihito,Kojima ^[11] ; Kensei,Yamaguchi ^[14]

作者单位： National Cancer Center Hospital East, Kashiwa, Japan. kshitara@east.ncc.go.jp.;Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan. kshitara@east.ncc.go.jp. ^[1] Seoul National University College of Medicine, Seoul, Republic of Korea. ^[2] National Cancer Center Hospital, Tokyo, Japan. ^[3] Osaka International Cancer Institute, Osaka, Japan. ^[4] Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. ^[5] Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. ^[6] Kindai University Hospital, Osaka, Japan. ^[7] Niigata Cancer Center Hospital, Niigata, Japan. ^[8] Osaki Citizen Hospital, Osaki, Japan. ^[9] National Hospital Organization Shikoku Cancer Center, Ehime, Japan. ^[10] Daiichi Sankyo Co. Ltd, Tokyo, Japan. ^[11] Daiichi Sankyo Inc., Basking Ridge, NJ, USA. ^[12] Daiichi Sankyo RD Novare Co. Ltd, Tokyo, Japan. ^[13] Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. ^[14]